Role of mirtazapine in the treatment of antipsychotic-induced akathisia

Annals of Pharmacotherapy

Volumn 42, Issue 6, 2008, Pages 841-846

  Hieber, Robin ^a   Dellenbaugh, Timothy ^b   Nelson, Leigh Anne ^c  

^a Western Missouri Mental Health Center   (United States)

^b SHANDONG MENTAL HEALTH CENTER   (China)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

Akathisia; Extrapyramidal symptoms; Mirtazapine

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PROPRANOLOL; RISPERIDONE;

ADULT; AKATHISIA; ARTICLE; BIPOLAR DISORDER; BRADYCARDIA; CASE REPORT; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DROWSINESS; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; HAMILTON SCALE; HUMAN; HYPOTENSION; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIFORM DISORDER; SEDATION; SIDE EFFECT;

ADRENERGIC ALPHA-ANTAGONISTS; ADRENERGIC BETA-ANTAGONISTS; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; MIANSERIN; PROPRANOLOL; RECEPTORS, SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 44649100899     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K672     Document Type: Article

References (38)

1. Neuroleptic-induced acute akathisia. In: Diagnostic and statistical manual of mental disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association, 2000:800-2.
2. Braude WM, Barnes TR, Gore SM. Clinical characteristics of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 1983;143:139-50.
3. Van Putten T, May PRA, Marder SR. Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 1984;41:1026-39.
4. Janno S, Holi M, Tuisku K, Wahlbeck K. Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. Am J Psychiatry 2004;161:160-3.
5. Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003;29:547-58.
6. Shear MK, Frances A, Weiden P. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol 1983;3:235-6.
7. Drake RE, Ehrlich J. Suicide attempts associated with akathisia. Am J Psychiatry 1985;142:499-501.
8. Atbasoglu EC, Schultz SK, Andreasen NC. The relationship of akathisia with suicidally and depersonalization among patients with schizophrenia. J Neuropsychiatry Clin Neurosci 2001;13:336-41.
9. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974;31:67-71.
10. Fleischhacker WW, Roth SD, Kane JM. The pharmacologic treatment of neuroleptic-induced akathisia. J Clin Psychopharmacol 1990;10:12-21.
11. Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73-81.
12. Lima AR, Bacalcthuk J, Barnes TRE, Soares-Weiser K. Propranolol as a primary treatment of neuroleptic-induced akathisia. Cochrane Database Systematic Rev 2007:4.
13. Lane RM. SSRI-induced extrapyramidal side-effects and akathisia: implications for treatment. J Psychopharmacol 1998;12:192-214.
14. Poyurovsky M, Weizman A. Serotonin-based pharmacotherapy for acute neuroleptic-induced akathisia: a new approach to an old problem. Br J Psychiatry 2001;179:4-8.
15. Weiss D, Aizenberg D, Hermesh H, et al. Cyproheptadine treatment in neuroleptic-induced akathisia. Br J Psychiatry 1995;167:483-6.
16. Fischel T, Hermesh H, Aizenberg D, et al. Cyproheptadine versus propranolol for the treatment of acute neuroleptic-induced akathisia: a comparative double-blind study. J Clin Psychopharmacol 2001;21:612-5.
17. 2A antagonist trazodone. Clin Neuropharmacol 2003;26:137-41.
18. Miller CH, Fleischhacker WW, Ehrmann H, Kane JM. Treatment of neuroleptic induced akathisia with the 5-HT2 antagonist ritanserin. Psychopharmacol Bull 1990;26:373-6.
19. Miller CH, Hummer M, Pycha R, Heischhacker WW. The effect of ritanserin on treatment-resistant neuroleptic induced akathisia: case reports. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:247-51.
20. Fuchs C, Weizman A. Low-dose mianserin in the treatment of acute neuroleptic-induced akathisia. J Clin Psychopharmacol 1998;18:253-4.
21. 2 antagonist mianserin. Br J Psychiatry 1999;174:238-42.
22. Poyurovsky M, Weizman A. Mirtazapine for neuroleptic-induced akathisia (letter). Am J Psychiatry 2001;158:819.
23. Wilson MS. Mirtazapine for akathisia in bipolar disorder. J Clin Psychopharmacol 2005;25:394-5.
24. Ranjan S, Chandra PS, Chaturvedi SK, Prabhu SC, Gupta A. Atypical antipsychotic-induced akathisia with depression: therapeutic role of mirtazapine. Ann Pharmacother 2006;40:771-4. Epub 28 Mar 2006. DOI 10.1345/aph.1G561
25. Poyurovsky M, Epshtein S, Fuchs C, Schneidman M, Weizman R, Weizman A. Efficacy of low-dose mirtazapine in neuroleptic-induced akathisia: a double-blind randomized placebo-controlled pilot study. J Clin Psychopharmacol 2003;23:305-8.
26. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: a new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry 2006;59:1071-7.
27. de Boer TH. The pharmacologic profile of mirtazapine. J Clin Psychiatry 1996;57(suppl 4):19-25.
28. Poyurovsky M, Weizman A. Lack of efficacy of the 5-HT3 receptor antagonist granisetron in the treatment of acute neuroleptic-induced akathisia. Int Clin Psychopharmacol 1999;14:357-60.
29. Zoccali R, Muscatello MR, Cedro C, et al. The effect of mirtazapine augmentation of clozapine in the treatment of negative symptoms of schizophrenia: a double-blind, placebo-controlled study. Int Clin Psychopharmacol 2004;19:71-6.
30. Berk M, Ichim C, Brook S. Efficacy of mirtazapine add on therapy to haloperidol in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study. Int Clin Psychopharmacol 2001;16:87-92.
31. Barnes TRE. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-6.
32. Adler LA, Peselow E, Rosenthal M, Angrist B. A controlled comparison of the effects of propranolol, benztropine, and placebo in akathisia: an interim analysis. Psychopharmacol Bull 1993;29:283-6.
33. Schule C, Baghai TC, Eser D, et al. Mirtazapine monotherapy versus combination therapy with mirtazapine and aripiprazole in depressed patients without psychotic features: a 4-week open-label parallel-group study. World J Biol Psychiatry 2007;8:112-22.
34. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord 2005;86:99-104.
35. Papakostas GI, Petersen TJ, Kinrys G, et al. Aripiprazole augmentation of selective serotonin reuptake inhibitors for treatment-resistant depressive disorder. J Clin Psychiatry 2005;66:1326-30.
36. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry 2005;66:1216-20.
37. Markkula J, Lauerma H. Mirtazapine-induced restless legs. Hum Psychopharmacol 1997;12:497-9.
38. Girishchandra BG, Johnson L, Cresp RM, Orr KG. Mirtazapine-induced akathisia. Med J Aust 2002;176:242.